This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

58/100

✓ Peer-reviewed alzhub usefulness score 58 out of 100. How common it is

Topic: Risk, prevention and care in population studies

Over 7,430,253 person-years of follow-up, 11,345 dementia cases occurred (10,863 AD and 2,159 VaD). Adjusted SHRs for MASLD were 1.10 (1.07-1.13) for AD and 1.20 (1.13-1.27) for VaD. For MetALD, SHRs were 0.90 (0.87-0.94) for AD and 1.53 (1.40-1.66) for VaD. Dementia risk in both MASLD and MetALD increased over longer periods, with MetALD initially linked to increased VaD risk and decreased AD risk, which reversed after three years. MASLD and MetALD were associated with increased risks of AD and VaD; MetALD showing a stronger association with VaD. Understanding the distinct effects of different SLD subtypes on dementia is crucial for improving risk assessment and management strategies.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Shin, W.-Y., Kang, E. S., Oh, Y. H., Sha, M., Xia, Q., Jeong, S., et al. (2025). Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study. BMC Gastroenterology. https://doi.org/10.1186/s12876-025-03814-1

Vancouver

Shin W.-Y, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, et al. Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study. BMC Gastroenterology. 2025. doi:10.1186/s12876-025-03814-1. PMID: 40301749.

BibTeX

@article{shin2025-40301749,
  author  = {Shin, Woo-Young and Kang, Eun Seok and Oh, Yun Hwan and Sha, Meng and Xia, Qiang and Jeong, Seogsong and Cho, Yoosun},
  title   = {{Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study}},
  journal = {BMC Gastroenterology},
  year    = {2025},
  doi     = {10.1186/s12876-025-03814-1},
  pmid    = {40301749},
  url     = {https://doi.org/10.1186/s12876-025-03814-1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Over 7,430,253 person-years of follow-up, 11,345 dementia cases occurred (10,863 AD and 2,159 VaD).
Adjusted SHRs for MASLD were 1.10 (1.07-1.13) for AD and 1.20 (1.13-1.27) for VaD.
For MetALD, SHRs were 0.90 (0.87-0.94) for AD and 1.53 (1.40-1.66) for VaD.
Dementia risk in both MASLD and MetALD increased over longer periods, with MetALD initially linked to increased VaD risk and decreased AD risk, which reversed after three years.
MASLD and MetALD were associated with increased risks of AD and VaD; MetALD showing a stronger association with VaD.

Why it matters

This cohort study found that MASLD and MetALD were associated with increased risks of Alzheimer's disease and vascular dementia, with MetALD showing a stronger association with vascular dementia. It suggests that understanding the distinct effects of different liver disease subtypes on dementia could improve risk assessment and management strategies.

New to this subject? Start with our plain-English guide: Alzheimer's in numbers →

Study details

Study designcohort study
Participants296,001
Evidence strengthModerate

How this study scored 58/100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (BMC Gastroenterology)
Journal's citation record	1 / 4	BMC Gastroenterology: journal h-index 122 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	4 / 4	296,001 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 15 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	5.0 citations a year over 3 year(s) since 2025
Impact for its field and year	4 / 6	Cited 9.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	2 / 4	Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Yoosun Cho: h-index 15 (OpenAlex, whole career)
Institution's track record	1 / 3	Shanghai Jiao Tong University: institution h-index 975 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40301749)
Free to read	2 / 2	Free to read
Total	58 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in How common it is

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Similar studies

More on How common it is

See all studies in How common it is →